Immunovant Inc’s filing revealed that its Chief Technology Officer Stout Jay S unloaded Company’s shares for reported $28471.0 on Apr 23 ’25. In the deal valued at $14.79 per share,1,925 shares were sold. As a result of this transaction, Stout Jay S now holds 209,243 shares worth roughly $3.04 million.
Then, Geffner Michael sold 2,349 shares, generating $34,742 in total proceeds. Upon selling the shares at $14.79, the Chief Medical Officer now owns 225,370 shares.
Before that, Barnett Eva Renee sold 2,993 shares. Immunovant Inc shares valued at $44,566 were divested by the Chief Financial Officer at a price of $14.89 per share. As a result of the transaction, Barnett Eva Renee now holds 396,774 shares, worth roughly $5.77 million.
Jefferies initiated its Immunovant Inc [IMVT] rating to a Hold in a research note published on March 03, 2025; the price target was $20. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who decreased its forecast for the stock in early January from “an Outperform” to “a Peer perform”. Oppenheimer maintained its rating on October 09, 2024. It rated IMVT as “an Outperform”.
Price Performance Review of IMVT
On Monday, Immunovant Inc [NASDAQ:IMVT] saw its stock jump 3.78% to $14.55. Over the last five days, the stock has lost -4.40%. Immunovant Inc shares have fallen nearly -41.26% since the year began. Nevertheless, the stocks have fallen -51.11% over the past one year. While a 52-week high of $34.47 was reached on 01/02/25, a 52-week low of $12.72 was recorded on 04/09/25. SMA at 50 days reached $16.64, while 200 days put it at $24.51.
Levels Of Support And Resistance For IMVT Stock
The 24-hour chart illustrates a support level at 14.24, which if violated will result in even more drops to 13.92. On the upside, there is a resistance level at 15.02. A further resistance level may holdings at 15.48. The Relative Strength Index (RSI) on the 14-day chart is 44.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.61, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.36%. Stochastics %K at 30.19% indicates the stock is a holding.
The most recent change occurred on March 28, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
